QUICK SEARCH:   [advanced] Author: Keyword(s):
Home     Help     Feedback     Subscriptions     Archive     Search     Table of Contents

This Article Figures Only Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ma, Z. Articles by Gonias, S. L. Search for Related Content PubMed PubMed Citation Articles by Ma, Z. Articles by Gonias, S. L.

Endogenously produced urokinase-type plasminogen activator is a major determinant of the basal level of activated ERK/MAP kinase and prevents apoptosis in MDA-MB-231 breast cancer cells

¹ Departments of Pathology,
² Cell Biology², and
³ Biochemistry and Molecular Genetics, University of Virginia School of Medicine, Charlottesville, VA 22908, USA

*Author for correspondence (e-mail: slg2t{at}virginia.edu)

Accepted June 7, 2001

Urokinase-type plasminogen activator (uPA) binds to the uPA receptor (uPAR) and activates the Ras-extracellular signal-regulated kinase (ERK) signaling pathway in many different cell types. In this study, we demonstrated that endogenously produced uPA functions as a major determinant of the basal level of activated ERK in MDA-MB-231 breast cancer cells. When these cells were cultured in the presence of antibodies that block the binding of uPA to uPAR, the level of phosphorylated ERK decreased substantially. Furthermore, conditioned medium from MDA-MB-231 cells activated ERK in MCF-7 cells and this response was blocked by uPA-specific antibody. The mitogen-activated protein kinase kinase inhibitor, PD098059, decreased expression of uPA and uPAR in MDA-MB-231 cells. Thus, uPA and the uPAR-ERK signaling pathway form a positive feedback loop in these cells. When this feedback loop was disrupted with uPA- or uPAR-specific antibody, uPA mRNA-specific antisense oligodeoxynucleotides or PD098059, cell growth was inhibited and apoptosis was promoted, as determined by the increase in cytoplasmic nucleosomes and caspase-3 activity. Treating the cells simultaneously with PD098059 and uPA- or uPAR-specific antibody did not further promote apoptosis, compared with either reagent added separately, supporting the hypothesis that uPAR and ERK are components of the same cell growth/survival-regulatory pathway. The ability of uPA to signal through uPAR, maintain an elevated basal level of activated ERK and inhibit apoptosis represents a novel mechanism whereby the uPA-uPAR system may affect breast cancer progression in vivo.

Key words: Urokinase-type plasminogen activator, uPAR, MAP kinase/extracellular signal-regulated kinase, Apoptosis, Breast cancer

This article has been cited by other articles:

				Z. Ma, K. S. Thomas, D. J. Webb, R. Moravec, A. M. Salicioni, W. M. Mars, and S. L. Gonias Regulation of Rac1 activation by the low density lipoprotein receptor-related protein J. Cell Biol., December 23, 2002; 159(6): 1061 - 1070. [Abstract] [Full Text] [PDF]

				D. Palmieri, J. W. Lee, R. L. Juliano, and F. C. Church Plasminogen Activator Inhibitor-1 and -3 Increase Cell Adhesion and Motility of MDA-MB-435 Breast Cancer Cells J. Biol. Chem., October 18, 2002; 277(43): 40950 - 40957. [Abstract] [Full Text] [PDF]

				M. J. Duffy Urokinase Plasminogen Activator and Its Inhibitor, PAI-1, as Prognostic Markers in Breast Cancer: From Pilot to Level 1 Evidence Studies Clin. Chem., August 1, 2002; 48(8): 1194 - 1197. [Abstract] [Full Text] [PDF]